Ranbaxy
Under fire Ranbaxy sold to Sun Pharma for $4 billion
April 7, 2014Manufacturing and Production, Sales and Marketing FDA, Ranbaxy, Sun Pharma, deal, hamburg, manufacturing
Sun Pharmaceutical Industries has bought struggling drugmaker Ranbaxy Laboratories in a deal that will see the two companies become the …
Ranbaxy hit with second generic Lipitor recall
March 10, 2014Manufacturing and Production, Sales and Marketing Daiichi Sankyo, FDA, Ranbaxy, hamburg, manufacturing
India’s largest native generic drugmaker Ranbaxy has come under greater pressure this week after the US has again sent out …
FDA extends Ranbaxy ban
January 27, 2014Manufacturing and Production, Sales and Marketing API, FDA, Ranbaxy, toansa
India-based generic manufacturer Ranbaxy Laboratories has been dealt a further blow as the US regulator has banned more of its …
Ranbaxy quality issues hit sixth plant; seeks Diovan workaround
January 20, 2014Manufacturing and Production FDA, Ranbaxy, fines, manufacturing
Yet another plant operated by India’s Ranbaxy has been held up by US Food and Drug Administration over quality deficiencies, …
FDA throws Ranbaxy a manufacturing lifeline
October 15, 2013Manufacturing and Production FDA, Ranbaxy, recall
Problems have plagued Ranbaxy’s manufacturing operations in the last couple of years, but it enjoyed a bit of light relief …
Ranbaxy taps into Malaysian growth with second facility
August 9, 2013Manufacturing and Production ASEAN, Ranbaxy, asian, malaysian
Indian drugmaker Ranbaxy has signed a deal to construct a new $35 million manufacturing facility in Malaysia that will triple …
Ranbaxy facing another facility problem?
June 26, 2013Manufacturing and Production FDA, Ranbaxy
Another facility operated by Ranbaxy Laboratories in India is reported to have failed an inspection by the FDA, potentially adding …
Nine fined in EU pay-for-delay deals
June 20, 2013Manufacturing and Production, Sales and Marketing EU, Lundbeck, Merck, Ranbaxy
Nine pharma firms have been handed hefty fines by the European Commission over allegations that they willingly blocked generic versions …
Ranbaxy unit fined $500m for selling adulterated drugs
May 14, 2013Manufacturing and Production FDA, GMP, Ranbaxy, fine, generics
Ranbaxy’s US subsidiary has agreed to pay fines and penalties totalling $500 million after pleading guilty to charges of manufacturing …
Ranbaxy suspends atorvastatin manufacturing after recall
November 30, 2012Manufacturing and Production FDA, Ranbaxy, atorvastatin, recall
Ranbaxy Laboratories has called a halt to manufacturing its generic atorvastatin product until it can get to the bottom of …
Glass particles force recall of Ranbaxy Lipitor
November 27, 2012Manufacturing and Production, Sales and Marketing Daiichi Sankyo, Lipitor, Pfizer, Ranbaxy, recall
Ranbaxy Pharmaceuticals is recalling around 40 batches of its generic atorvastatin tablets after discovering that some of the product may …
Pharma manufacturing news in brief
September 17, 2012Manufacturing and Production Ampio, DPT Labs, Ethypharm, ICH, PC Pharma, Ranbaxy
Ranbaxy and PC Pharma unveil new facility investments, Ethypharm will manufacture Ampio drug, DPT Labs is warned by the FDA …
Generic Actos gains FDA approval
August 20, 2012Sales and Marketing Actos, Mylan, Ranbaxy, Takeda, diabetes, generic
Takeda’s big-selling diabetes pill Actos will have its US sales decimated after the FDA approves three copycat versions of the …
Ranbaxy launches generic Lipitor in Europe
March 6, 2012Research and Development, Sales and Marketing Lipitor, Pfizer, Ranbaxy, atorvastatin, generics
Ranbaxy has launched its generic version of Pfizer’s Lipitor in Europe, months ahead of its May expiration date. The Indian …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
